CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04517669
NCT04517669N/ACompleted

A Non-Interventional Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis

Pfizer·observational·Posted Aug 18, 2020·Updated Oct 14, 2025

In Brief

An observational study for Psoriatic Arthritis. Completed, enrolled 116 participants across 41 sites in 8 countries.

Detailed Summary

This is a Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis in order to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and Quality of Life, in a real-world setting over a 12-month observation period

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Denmark, Finland, France, Israel, Netherlands, Spain, Sweden
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 18, 2020
Enrollment StartMay 17, 2021
Primary CompletionJul 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.9 years ago